Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers

卵巢癌生物标志物开发糖组学实验室

基本信息

批准号：
10299805
负责人：
KAREN L. ABBOTT
金额：
$ 47.96万
依托单位：
FLORIDA INTERNATIONAL UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-11-10 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10299805
关键词：
Antibodies Arkansas Ascites Binding Binding Proteins Biological Assay Biological Markers Biotin Blood C-terminal Cancer Biology Cancer Patient Carbohydrates Cell Communication Cells Complex Detection Development Diagnosis Disease Elements Enzymes Epithelial ovarian cancer Future GPAA1 gene GPI Membrane Anchors Glycopeptides Glycoproteins Glycosylphosphatidylinositols Goals Growth Immune Immunoglobulin G Label Link Malignant Female Reproductive System Neoplasm Malignant Neoplasms Malignant neoplasm of ovary Mammalian Oviducts Mass Spectrum Analysis Medical Methods Monitor Non-Malignant Notch Signaling Pathway Ovarian Endometrioid Adenocarcinoma Ovary Papillary Pathway interactions Peptides Polysaccharides Population Prognostic Marker Proteins Quality of life Recurrence Research Research Personnel Role Sampling Science Screening for Ovarian Cancer Serous Serous Cystadenocarcinoma Serum Side Site Specificity Stage at Diagnosis Structure Survival Rate Symptoms Technology Therapeutic Intervention Time Tissues Universities Validation advanced disease alpha Toxin biomarker discovery cancer biomarkers cancer cell cancer stem cell carbohydrate binding protein defined contribution glycosylation glycosyltransferase improved laboratory development lipid structure medical schools multidisciplinary notch protein potential biomarker stem cell population sugar tumor tumor growth tumor microenvironment tumor progression

项目摘要

ABSTRACT Ovarian cancer is a silent killer with few early symptoms and advanced disease often present at the time of diagnosis. This cancer is the most lethal of all gynecologic malignancies with over 20,000 new cases diagnosed each year. The 5 year survival rates for ovarian cancer dramatically improve when the disease is diagnosed at an earlier stage. Therefore, the long term goal of the Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers is to apply the most advanced technologies toward the goal of identifying glycoprotein and glycan markers that can detect ovarian cancer early. We are a multidisciplinary team with expertise in cancer biology, glycomics, glycan array analysis, and translational glycoimmunology from investigators at the University of Arkansas for Medical Sciences (UAMS), the Complex Carbohydrate Research Center (CCRC) at the University of Georgia, and the Harvard Medical School Center for Glycoscience at Harvard University. The investigators at UAMS specialize in biomarker discovery using glycomic methods and functional studies of glycosyltransferase enzymes in ovarian cancer progression, the co-investigators at the CCRC specialize in the mass spectrometry identification of O-linked glycans present on the Notch receptor and the functional analysis of these glycans in Notch activation, and the co-investigators at Harvard specialize in the development of antibodies binding to tumor-specific glycans and the development of glycopeptide arrays. The aims of this application are (1) To develop and validate N-linked and O-linked glycoforms for the detection of ovarian cancer and (2) To discover and develop glycosylphosphatidylinositol (GPI) anchored protein glycoforms and GPI anchor binding proteins for the detection of ovarian cancer.

抽象的卵巢癌是一种无声杀手，早期症状很少，晚期疾病通常在发病时出现。诊断。这种癌症是所有妇科恶性肿瘤中最致命的，有超过 20,000 例新病例每年都会确诊。当卵巢癌得到有效治疗后，其 5 年生存率会显着提高在早期阶段就被诊断出来。因此，糖组学实验室的长期目标是发展卵巢癌生物标志物的研究旨在应用最先进的技术来实现识别卵巢癌生物标志物的目标糖蛋白和聚糖标记物可以早期检测卵巢癌。我们是一个多学科团队癌症生物学、糖组学、聚糖阵列分析和转化糖免疫学方面的专业知识阿肯色医学大学 (UAMS) 的研究人员研究了复杂碳水化合物乔治亚大学研究中心 (CCRC) 和哈佛医学院研究中心哈佛大学糖科学。 UAMS 的研究人员专门从事生物标志物发现，使用糖组学方法和糖基转移酶在卵巢癌进展中的功能研究， CCRC 的共同研究人员专门从事 O-连接聚糖的质谱鉴定 Notch 受体以及这些聚糖在 Notch 激活中的功能分析，以及共同研究人员哈佛大学专注于开发与肿瘤特异性聚糖结合的抗体以及开发糖肽阵列。该应用程序的目的是 (1) 开发和验证 N-连接和 O-连接用于检测卵巢癌的糖型以及（2）发现和开发糖基磷脂酰肌醇 (GPI) 锚定蛋白糖型和 GPI 锚定结合蛋白用于检测卵巢癌。